Catalent, Inc. (CTLT) has seen significant changes in shareholding as the
New York State Teachers Retirement System and
Assenagon Asset Management decreased their stakes, while
Vanguard Group raised its stake. Moreover,
Novo Nordisk's offer to acquire the company has gained traction. The company recently completed a
$25 Million expansion of its clinical supply facility in Schorndorf, Germany. Regulatory hurdles have also been encountered with a request for more information from the FTC and regulatory control lapses highlighted at a Catalent plant scheduled for sale to Novo Nordisk. Multi-billion dollar private debt led by
Ares and Blue Owl is backing the Catalent deal. The company’s Q3 2024 fiscal earnings underperformed estimates, but the gross margin was up.
M & A activities, like the announcement of
Novo Nordisk's $16.5 billion acquisition of Catalent, essentially underscore the company's increasing value. Activist company
Elliott made inroads at Catalent, intending to build value; the move significantly affected stock value.
Catalent CTLT News Analytics from Mon, 29 Aug 2022 07:00:00 GMT to Sun, 25 Aug 2024 11:42:06 GMT -
Rating 8
- Innovation -1
- Information 7
- Rumor -7
